NOUMED LIFE SCIENCES LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to note 1.2 to the financial statements, which describes the directors' assessment of the company's ability to continue as a going concern. Since the year end, the company has restructured its financing arrangements and completed the sale of an investment, generating liquidity to support ongoing operations. These matters indicate that the going concern basis of preparation depends on the successful implementation of these measures.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -45.3%

  £31,867,003 → £17,419,702

• Cash

  -89.3%

  £811,054 → £86,902

  lowest in 5 filed years

• Net assets

  -252.4%

  -£6,692,424 → -£23,585,359

  lowest in 5 filed years

• Employees

  -1.3%

  154 → 152

• Operating profit

  -114.9%

  -£7,841,106 → -£16,854,217

  lowest in 4 filed years

• Profit before tax

  -104.7%

  -£9,632,639 → -£19,720,608

  lowest in 5 filed years

• Wages

  +1.3%

  £5,677,580 → £5,750,162

  highest in 5 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

MGI Midgley Snelling LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 1.2 to the financial statements, which describes the directors' assessment of the company's ability to continue as a going concern. Since the year end, the company has restructured its financing arrangements and completed the sale of an investment, generating liquidity to support ongoing operations. These matters indicate that the going concern basis of preparation depends on the successful implementation of these measures.”

Group structure

1. NOUMED LIFE SCIENCES LIMITED · parent
   1. Noumed Pharmaceuticals Pty Limited 70% · Australia
   2. Noumed Pharmaceuticals Limited 70% · New Zealand

Significant events

• “In Jan 2025, 130 non-redeemable preference shares were issued in exchange for £2.04m.”
• “The company has completed the sale of its shares in Noumed Pharmaceuticals Pty Limited for a total consideration of AU$18 million. The purchase price will be settled in three tranches: AU$6 million on closing, AU$6 million within 20 business days of closing, and AU$6 million by 31 December 2025.”
• “Additional financing has been obtained since the year end be ng an accounts receivable facility and a new related party loan. This along with refinancing of the bank loan debt is further disclosed in the going concern accounting policy.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

6

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.